Runway Growth Finance (RWAY) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
12 Aug, 2026Executive summary
Completed the SWK Holdings acquisition, expanding the portfolio into healthcare and life sciences, and immediately enhancing diversification and earnings capacity.
Net assets as of June 30, 2026, were $502.6 million, with a net asset value per share of $11.91.
Investment portfolio at fair value reached $1.2 billion, up from $927.4 million at year-end 2025, with 57 debt and 101 equity investments across 79 companies.
Appointed Michael Rovner as Co-CEO and Co-CIO, effective August 2026, strengthening leadership.
Maintained a high dividend yield (~23%) and continued share repurchase program, with $3.1 million repurchased as of August 3, 2026.
Financial highlights
Total investment income for Q2 2026 was $37.0 million, up from $35.1 million in Q2 2025 and $29.5 million in Q1 2026.
Net investment income for Q2 2026 was $18.2 million ($0.43/share), compared to $13.9 million ($0.38/share) in Q2 2025.
Portfolio fair value increased 35% to $1.2 billion, driven by the SWK acquisition.
Net realized loss on investments was $45.3 million, mainly from Marley Spoon and Blueshift restructurings, offset by a net change in unrealized gain of $54.3 million.
Net increase in net assets from operations for Q2 2026 was $27.2 million ($0.65 per share), up from $16.8 million ($0.45 per share) year-over-year.
Outlook and guidance
Dividend of $0.33 per share declared for Q3 2026, with expectations of >100% coverage for the year.
Management anticipates continued portfolio diversification, stable dividend, and sufficient liquidity to support near-term capital requirements.
SWK acquisition expected to provide ongoing accretion of $0.05 per share quarterly.
Adviser and affiliates committed to purchasing up to 10% of outstanding shares if trading at or below 70% of NAV.
Latest events from Runway Growth Finance
- SWK acquisition expands healthcare exposure as Q1 income dips and share repurchase is launched.RWAY
Q1 2026 - Annual meeting to elect directors and ratify Deloitte as auditor, with strong governance in place.RWAY
Proxy filing - Shareholders will vote on two director nominees and auditor ratification at the June 2026 virtual meeting.RWAY
Proxy filing - Lower Q4 2025 income, but strong portfolio, stable dividends, and SWK acquisition drive growth.RWAY
Q4 2025 - Vote sought on new advisory agreement, director election, and adjournment; no fee or strategy changes.RWAY
Proxy Filing - $220M NAV-for-NAV merger boosts healthcare exposure and scale, closing by early 2026.RWAY
M&A Announcement - Q3 2024 saw $75.3M in new loans, strong yields, and a strategic adviser acquisition pending.RWAY
Q3 2024 - Q2 2024 featured strong yields, new investments, and active capital return programs.RWAY
Q2 2024 - NAV per share rose to $13.79 as BC Partners Credit integration enhanced growth capacity.RWAY
Q4 2024